Bryan Silvey

Bryan Silvey has been in the biopharmaceutical industry for 30 years in both Quality technical roles and Regulatory Affairs CMC leadership positions having responsibilities for both global products and facilities lifecycle management. Global experience in regulatory authority requirements and expectations in the CMC space with biologics has proved a grounding platform of quality principles that he has applied to successful development and commercialization of two (2) CAR T-Cell therapies while at Kite (a Gilead Company). Prior to Kite, Bryan had increasing Quality/CMC roles at BMS, and Baxter Healthcare.

As Head of Quality for A2 Biotherapeutics, a clinical stage cell therapy discovery and development company, this journey in CMC science continues to push forward in an effort to address unmet cancer patient needs. Bryan holds a Bachelor of Chemistry degree from Colorado State University.